MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 67 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 0.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $332,000 | -81.8% | 80,000 | -94.0% | 0.04% | -85.5% |
| Q2 2017 | $1,824,000 | -22.6% | 1,331,421 | 0.0% | 0.31% | -32.8% |
| Q1 2017 | $2,357,000 | +74.1% | 1,331,421 | -0.7% | 0.46% | +34.4% |
| Q4 2016 | $1,354,000 | -44.5% | 1,340,588 | 0.0% | 0.34% | -13.6% |
| Q3 2016 | $2,440,000 | +64.1% | 1,340,588 | +14.5% | 0.40% | +2.8% |
| Q2 2016 | $1,487,000 | -51.6% | 1,170,643 | +105.0% | 0.39% | -42.0% |
| Q1 2016 | $3,071,000 | -29.6% | 570,908 | 0.0% | 0.67% | +4.2% |
| Q4 2015 | $4,362,000 | +222.6% | 570,908 | +252.2% | 0.64% | +271.5% |
| Q3 2015 | $1,352,000 | -61.0% | 162,120 | -45.7% | 0.17% | -49.3% |
| Q2 2015 | $3,463,000 | +80.4% | 298,533 | +39.8% | 0.34% | +69.5% |
| Q1 2015 | $1,920,000 | -37.9% | 213,533 | -27.3% | 0.20% | -62.0% |
| Q4 2014 | $3,094,000 | +62.9% | 293,533 | 0.0% | 0.53% | +124.3% |
| Q3 2014 | $1,899,000 | – | 293,533 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 6,502,840 | $13,201,000 | 3.58% |
| Lion Point Capital, LP | 6,374,740 | $12,940,000 | 3.42% |
| Granite Point Capital Management, L.P. | 1,889,100 | $3,835,000 | 2.17% |
| Bain Capital Life Sciences Investors, LLC | 5,942,735 | $12,064,000 | 2.04% |
| Asymmetry Capital Management, L.P. | 855,318 | $1,736,000 | 1.90% |
| ACUTA CAPITAL PARTNERS, LLC | 1,038,000 | $2,107,000 | 1.02% |
| Bleichroeder LP | 1,250,000 | $2,538,000 | 0.66% |
| Boxer Capital, LLC | 4,800,000 | $9,744,000 | 0.66% |
| Avoro Capital Advisors LLC | 6,200,000 | $12,586,000 | 0.42% |
| Islet Management, LP | 1,000,000 | $2,030,000 | 0.30% |